Portfolio

Total Value
$2,547.83
Total P&L
+$847.23
+49.8%
Available
$1,200.5
Positions
5
Win Rate
68%
MarketOutcomeSharesAvg PriceCurrentP&LValue
Will FDA approve Lecanemab for early Alzheimer's by March 2026?
Will FDA approve Lecanemab for early Alzheimer's by March 2026?
YES
36265.7¢71.1¢$87.75$384.96
Will Eli Lilly's Donanemab receive full FDA approval by Q2 2026?
Will Eli Lilly's Donanemab receive full FDA approval by Q2 2026?
NO
59837.1¢73.3¢$0.76$443.31
Will FDA approve first CAR-T therapy for solid tumors by 2026?
Will FDA approve first CAR-T therapy for solid tumors by 2026?
YES
51564.7¢40.2¢+$286.33$274.73
Will Pfizer's RSV vaccine maintain FDA approval through 2025?
Will Pfizer's RSV vaccine maintain FDA approval through 2025?
NO
57950.1¢83.3¢+$111.45$433.12
Will FDA approve generic Ozempic by end of 2026?
Will FDA approve generic Ozempic by end of 2026?
YES
32154.3¢24.5¢+$213.80$944.56